News from UNITAID
UNITAID Signs Civil Society Engagement Plan
The NGOs and Communities Board Members and Liaison Officers met with the UNITAID Secretariat on 13 November 2015 to discuss UNITAID civil society engagement. One of the outcomes of that meeting was that the Secretariat agreed to draft principles to structure UNITAID...
UNITAID approves 3 new TB areas of intervention
GENEVA, 18 March 2016 - UNITAID will invest in increasing access to: improved and shorter treatments for drug-resistant tuberculosis (see the board approved resolution) better tuberculosis treatment for children (see the board approved resolution) preventive therapy...
UNITAID publishes disease narratives that help guide its investments
GENEVA, 17 November 2015 - UNITAID is working to achieve maximum possible health impact through investments aimed at people most exposed to disease and in greatest need. A primary goal of UNITAID is to identify how it can best contribute to the global response with...
UNITAID seeks proposals to scale up better TB treatment for children
GENEVA, 24 March - UNITAID today launched its latest call for funding proposals, focused on scaling up better tuberculosis (TB) treatment for children. Innovative approaches are being sought to ease adoption of new TB drugs and make them more accessible to children in...
New Initiative to boost Malaria Control and Combat Insect Resistance
Geneva, 1 February 2016: UNITAID and IVCC (Innovative Vector Control Consortium) today announced an initiative to expand the use of new anti-malarial insecticides to maintain the important role of mosquito control in combating malaria. The US $65.1 million initiative,...
UNITAID Welcomes Sub- Licences to make Hepatitis C Drug Widely Available
Geneva, 19 January 2016 – UNITAID welcomes agreements to manufacture a key Hepatitis C medicine and make it available in many low- and middle-income countries. The Medicines Patent Pool (MPP), which is fully funded by UNITAID, signed licenses for the generic...
The Medicines Patent Pool and Abbvie Sign Licensing Agreement to Increase Access to Crucial HIV treatments Throughout Africa
Geneva, 18 December 2015 — The Medicines Patent Pool (MPP) today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa....
UNITAID Reviews Landscape in Diagnostics Technology for HIV
UNITAID today released its 2015 HIV/AIDS Diagnostics Technology Landscape that summarizes the latest products and technologies to detect, stage and monitor HIV infection. The Landscape covers technologies including instruments for laboratories, multi-purpose platforms...